



## Near-Infrared Photoimmunotherapy for Cancer Treatment

Guest Editor:

**Dr. Hisataka Kobayashi**

Molecular Imaging Program,  
Center for Cancer Research,  
National Cancer Institute, NIH,  
Bethesda, MD 20892, USA

Deadline for manuscript  
submissions:

**closed (10 April 2024)**

### Message from the Guest Editor

Dear Colleagues,

Near-infrared photoimmunotherapy (NIR-PIT) is a newly developed, molecularly targeted cancer phototherapy involving conjugating a near-infrared silica-phthalocyanine dye, IRDye700DX (IR700), to monoclonal-antibody (mAb)-targeting cell-surface molecules. NIR-PIT targeting EGFR using cetuximab-IR700 conjugates is now undergoing a global Phase 3 clinical trial in late-stage head and neck squamous cell cancer patients, and was approved for clinical use under health insurance in Japan in September 2020. NIR-PIT is different from conventional photodynamic therapy (PDT) in photochemistry and cytotoxic mechanisms, resulting in a superior safety profile in preclinical and clinical studies.

Inviting contributions : This Special Issue welcomes research articles and review papers focused on a wide scope of NIR-PIT-related science, from basic photochemistry to preclinical and clinical NIR-PIT studies.

Dr. Hisataka Kobayashi  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

**Prof. Dr. Samuel C. Mok**

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

*Cancers* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)